Discussing AxSpA: Upadacitinib in nr-axSpA and certolizumab pegol by baseline MRI and CRP status
The IMID Forum
00:00
Clinical Outcomes of Certolizumab Pegol in Non-Radiographic Axial Spondyloarthritis
Analyzing the long-term effects of certolizumab pegol treatment in non-radiographic axial spondyloarthritis patients, focusing on Safety Follow-Up Extension from weeks 52 to 156 with a particular emphasis on MRI and CRP status subgroups to evaluate treatment response.
Transcript
Play full episode
